Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 15;129(16):2514-2521.
doi: 10.1002/cncr.34837. Epub 2023 May 18.

Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States

Corey Neff  1   2 , Mackenzie Price  1   2 , Gino Cioffi  1   3 , Carol Kruchko  1 , Kristin A Waite  1   3 , Jill S Barnholtz-Sloan  1   3   4 , Quinn T Ostrom  1   2   5   6
Affiliations
Free article

Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States

Corey Neff et al. Cancer. .
Free article

Abstract

Background: Primary brain tumors (BTs) are rare, but cause morbidity and mortality disproportionately to their incidence. Prevalence estimates population-level cancer burdens at a specified time. This study estimates the prevalence of malignant and non-malignant BTs in comparison to other cancers.

Methods: Incidence data were obtained from the Central Brain Tumor Registry of the United States (2000-2019, varying), a combined data set including the Center for Disease Control and Prevention's National Program of Cancer Registries and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Incidence of non-BT cancers were obtained from the United States Cancer Statistics (2001-2019). Incidence and survival estimates for all cancers were obtained from SEER (1975-2018). Complete prevalence as of December 31, 2019, was estimated using prevEst. Estimates were generated overall for non-BT cancers, by BT histopathology, age groups at prevalence (0-14, 15-39, 40-64, 65+ years), and sex.

Results: We estimated 1,323,121 individuals with a diagnosis of BTs at the date of prevalence. The majority of BT cases had non-malignant tumors (85.3%). Among all cancers, BTs were the most prevalent cancer type among those ages 15 to 39 years, second among those ages 0 to 14 years, and in the top five among those ages 40 to 64 years. The plurality of prevalent cases (43.5%) occurred among those ages 65+ years. Overall, females had a higher prevalence of BTs than males, with an overall female:male prevalence ratio of 1.68.

Conclusions: BTs contribute significantly to the cancer burden in the United States, particularly among those younger than age 65 years. Understanding complete prevalence is crucial for monitoring cancer burden to inform clinical research and public policy.

Keywords: Central Brain Tumor Registry of the United States; brain tumor; cancer; epidemiology; prevalence.

PubMed Disclaimer

References

REFERENCES

    1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24(suppl 5):v1-v95. doi:10.1093/neuonc/noab200
    1. Cancer Registries Amendment Act, 102nd Cong. § 515 (1992). Accessed July 21, 2020. https://www.govinfo.gov/content/pkg/STATUTE-106/pdf/STATUTE-106-Pg3372.pdf
    1. Benign Brain Tumor Cancer Registries Amendment Act, 107th Cong. § 260 (2002). Accessed July 21, 2020. http://www.gpo.gov/fdsys/pkg/PLAW-107publ260/pdf/PLAW-107publ260.pdf
    1. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21(22):3511-3526. doi:10.1002/sim.1304
    1. De Angelis R. MIAMOD/PIAMOD. Istituto Superiore di Sanità. Accessed November 4, 2022. http://www.eurocare.it/MiamodPiamod/tabid/60/Default.aspx#software

Publication types

LinkOut - more resources